Microsoft word - ixabepilone_monograph
FDA classification: Treatment for metastatic or locally advanced breast cancer .
Ixabepilone (aza-epothilone B) is a semi-synthetic and water-soluble epothilone analog, which is a group of
cytotoxic macrolide isolated from the myxobacterium Sorangium cellulosum . This agent is classified as a
novel class of drugs targeting microtubules in a mechanism of action similar to taxanes (e.g. paclitaxel), and
is particularly designed to provide enhanced antineoplastic activity  by overcoming problems associated
with taxane-based therapy (difficulties in formulation, administration, etc). Similar to paclitaxel, Ixabepilone
exerts its cytotoxic action by binding to the β-tubulin subunit in human cells, thereby preventing the
polymerization of these heterodimeric subunits and suppressing the dynamics of microtubules . As a
result, the formation of functional mitotic spindles during cell division is prohibited, the cell cycle arrests at
the G2/M checkpoint and subsequently apoptosis is induced leading to cytotoxicity . Ixabepilone is also
found to be less susceptible to drug resistance mechanisms on certain cancer cells, including the
overexpression of p-glycoprotein and MRP-1 efflux transporters and βIII-tubulin isoforms . In addition,
the drug demonstrated high activity against various paclitaxel-sensitive and paclitaxel-resistant models
including ovarian and breast cancer xenografts .
Ixabepilone is currently approved by the FDA for the treatment of metastatic or locally advanced breast
cancer . In combination with capecitabine, this drug demonstrated superior activity over capecitabine
alone , and this regimen is indicated for patients who fail to respond to taxanes and anthracyclines .
Ixabepilone can also be used as a monotherapy in patients who did not benefit from capecitabine, taxanes
The recommended dosage of Ixempra is 40 mg/m2 administered intravenously over 3 hours every 3 weeks.
Doses for patients with body surface area (BSA) greater than 2.2 m2 should be calculated based on 2.2 m2.
DOSE ADJUSTMENTS IN PATIENTS WITH HEPATIC IMPAIRMENT
Hepatic impaired patients should have Ixempra dose reduced according to the severity of impairment. The
following table summarizes the judging criteria.
DOSE ADJUSTMENTS IN PATIENTS EXPERIENCING TOXICITY
The dose of Ixempra should be reduced by 20% for patients having the following toxicity:
Grade 2 neuropathy (moderate) lasting ≥7 days
Grade 3 neuropathy (severe) lasting <7 days
Any grade 3 toxicity (severe) other than neuropathy
Neutrophil <500 cells/mm3 for ≥7 days
Platelets <25,000/mm3 or platelets <50,000/mm3 with bleeding
Ixempra should be discontinued in patients having the following toxicity:
Grade 3 neuropathy (severe) lasting ≥7 days or disabling neuropathy
According to Study 081, Ixabepilone monotherapy caused peripheral sensory neuropathy in 62% of patients.
It is the most common adverse effect requiring treatment discontinuation. 6% of patients in Study 081 had
the Ixabepilone monotherapy discontinued due to the development of neuropathy. Patients usually
experience symptoms of this adverse effect, including numbness, tingling and burning sensation in
extremities, hyperesthesia, hypoesthesia, paresthesia, discomfort, or neuropathic pain, early in the
treatment course. About 75% of those patients have new-onset or worsening neuropathy in the first 3
cycles of treatment. The neuropathy caused is generally reversible and could be managed by dose
reduction, delay and discontinuation. In Study 081, 87% of patients who had the dose reduced showed no
worsening or even improvement in their neuropathic condition. In a prospective study on
Ixabepilone-induced neuropathy in 47 patients, the median time of onset of this adverse effect was 144
days in 11 patients. 8 of them had the problem resolved in a median of 15 days but not for 3 of them even
after 746 days after symptoms onset.  According to a pooled analysis, diabetic patients may experience
more severe neuropathy, but it is not shown that patients with grade 1 neuropathy or those who had
received prior neurotoxic chemotherapy are at increased risk of this adverse effect.
Suppression of bone marrow can be manifested as leukopenia, thrombocytopenia and anemia, but it is
primarily expressed as neutropenia. In a monotherapy study, 54% of patients developed grade 3/4
neutropenia while 49% of patients developed grade 3/4 leukopenia. 3% and 5% of patients developed
febrile neutropenia and infection with neutropenia respectively. Patients may suffer from serious infections
during neutropenia which may even lead to deaths in 0.4% of patients. This risk is higher in patients with
impaired liver function and in patients receiving capecitabine at the same time. Since myelosuppression is
dose-related, management of this adverse effect involves dose reduction.
Other common adverse effects related to Ixabepilone include fatigue/asthenia 56% (Grade 3/4: 13%),
myalgia/arthralgia 49% (Grade 3/4: 8%), alopecia 48% (Grade 3/4: 0%), nausea 42% (Grade 3/4: 2%),
stomatitis/mucositis 29% (Grade 3/4: 6%), vomiting 29% (Grade 3/4: 1%), diarrhea 22% (Grade 3/4: 1%), and
musculoskeletal pain 20% (Grade 3/4: 3%).
Some patienes on Ixabepilone may develop hypersensitivity reactions like flushing, dyspnea, bronchospasm
and rash, and 1% of patients even experience severe hypersensitivity reactions like anaphylaxis. Therefore,
all patients should receive an H1 and an H2 antagonist approximately one hour before Ixabepilone infusion
and the patients should be monitored for any hypersensitivity reactions. If the patient develops
hypersensitivity reactions, the treatment should be stopped and supportive therapy including
corticosteroids and adrenaline should be given. If a patient who developed this adverse effect is to be
treated with Ixabepilone again, the infusion time should be prolonged and the patient should be
premedicated with a corticosteroid in addition to the H1 and H2 antagonist. Patients should not take
Ixabepilone in case of history of severe hypersensitivity reaction to Cremophor® EL or its derivatives.
There are reports of myocardial ischemia, supraventricular arrhythmia and ventricular dysfunction in
patients receiving Ixabepilone. These adverse effects are more common in combination therapy of
Ixabepilone and capecitabine (1.9%) than in capecitabine monotherapy (0.3%). Ixabepilone should be used
in caution in patients with heart disease. If a patient developed these adverse effects, the drug should be
Ixempra belongs to pregnancy category D and may cause harmful effects on fetus if given to pregnant
women. Therefore, patients should be advised not to become pregnant if they are under Ixempra therapy
and they should use appropriate contraceptive method. However, if Ixempra is used in pregnancy or if
patients become pregnant when they take this medication, they should be warned with the potential
hazards to the fetus. Up till now, there is scientific evidence concerning the use of Ixempra in pregnancy.
It is not known if Ixempra is secreted into breast milk or not. However, in view of potential harmful effects
of to the infants, nursing mother should either stop breast feeding or discontinue Ixempra therapy.
Compared to patients with normal liver function, patients with impaired liver function have increased
exposure (measured by area under the curve) to Ixempra after an equivalent dose. The increase in drug
exposure ranges from 22% to 81% depending on the severity of liver damage.
Dose reduction is therefore recommended when giving Ixempra as monotherapy in patients with liver
impairment. Because of this, a liver function test is recommended before starting Ixempra therapy.
Pharmacokinetically, Ixempra is minimally excreted through kidneys. In a population pharmacokinetic
analysis of Ixempra as monotherapy, mild to moderate renal insufficiency (CrCL >30 mL/min) has no
clinically significant effects on the pharmacokinetics of Ixempra. The effect of renal impairment on
combination therapy (with capecitabine) has not been evaluated in patient with CrCL <50 mL/min.
The following parameters should be monitored for adverse reactions of Ixempra:
numbness and tingling of limbs (for neuropathy)
any infections/blood count (for myelosuppression)
skin reactions e.g. utricaria and rash (for hypersensitivity reactions)
Ixempra is contraindicated in the following conditions:
patients with history of severe hypersensitivity reaction to agents containing Cremophor® EL or its
derivatives (eg, polyoxyethylated castor oil)
patients with decreased neutrophil count (< 1500 cells/mm3) or a platelet count (< 100,000
patients with impaired liver function (AST or ALT level higher than 2.5 times of upper normal limit or
bilirubin level higher than upper normal limit) and use in combination with capecitabine
Ixabepilone is a substrate of cytochrome P450 isoenzyme CYP3A4. Its in vivo oxidative metabolism depends
on the enzyme and thus inhibitors or inducers of the P450 3A4 enzyme are going to have drug
pharmacokinetic interactions with Ixabepilone. The most significant and documented interaction is its
interaction with ketoconazole. A study by S. Goel et al. demonstrated that injection of Ixabepilone with oral
ketoconazole produces a drug-drug interaction that increased the mean geometric AUC of Ixabepilone by
77.6% (2892 vs 1628ng/mL); and the maximum tolerated dose of Ixabepilone halved after
co-administration of ketoconazole to 20mg/m2.  This result is similar with the manufacturer’s note about
79% AUC increase with ketoconazole. The manufacturer recommends co-administration with potent
CYP3A4 inhibitors should be avoided, and dosage adjustment to 20mg/m2 should be done if there is no
alternative.  Increased plasma concentration of the drug leads to higher risk of toxicity and adverse drug
reactions. Frequent monitoring of peripheral blood counts is necessary if there are possible drug
interactions.  Conversely, inducers of CYP3A4 can lead to increased clearance of Ixabepilone and
Inhibitors of CYP3A4 which can potentially increase plasma level of Ixabepilone: [9, 10]
Drugs in Bold are potent inhibitors of CYP3A4 and should be avoided to be used with Ixabepilone.
Inducers of CYP3A4 which can potentially decrease plasma level of Ixabepilone: [9, 10]
Drugs in Bold are potent inducers of CYP3A4. Manufacturer suggests considering alternatives with less
The disturbance of CYP3A4 is the only mechanism known to cause interactions with Ixabepilone by now.
Ixabepilone is only available in IV formulation, therefore it would only interact with food that interfere with
Grapefruit juice is widely regarded as an agent to cause inhibition of CYP3A4 and is prone to drug-food
interactions. Although some literatures stated that grapefruit juice mainly inhibit intestinal CYP3A4 and has
little inhibition on hepatic CYP3A4 , the manufacturer regards it as a potent inhibitor and recommends
to avoid grapefruit juice to prevent increases in Ixabepilone level. 
St. John’s wort, which is used for anti-depression, is a renowned herb to cause drug-herb interaction as it is
an inducer of CYP3A4.  It may decrease Ixabepilone level unpredictably as noted by the manufacturer.
St. John’s wort should be avoided during Ixabepilone therapy. 
Intravenous administration of single dose 40 mg/m2 of to patients, the mean Cmax was 252 ng/mL, Tmax
was 3 hours and mean AUC was 2143 ng hr/mL (CV 48%). In cancer patients, the pharmacokinetics of
ixebepilone was linear at doses of 15 to 57 mg/m2.
The mean volume of distribution of 40 mg/m2 Ixabepilone was greater than 1000 L. Binding of ixebepilone
to human serum proteins ranged from 67 to 77%, and the blood-to-plasma concentration ratios in human
blood ranged from 0.65 to 0.85 over a concentration range of 50 to 5000 ng/mL.
Ixebepilone is extensively metabolized in the liver by CYP3A4 enzyme. The metabolites of ixebepilone were
not active against human tumor cells. In vitro studies shows that the clinically relevant concentrations of
ixebepilone neither inhibit nor induce the activity of CYP1A2, CYP2B6, CYP2C9, or CYP3A4 in cultured
human hepatocytes. Hence, ixebepilone will not affect the plasma levels of drugs which are substrates of
Ixebepilone has a half life of about 52 hours. It is eliminated mainly as charged form. After intravenous
administration of ixebepilone, approximately 86% and 7.2% of the dose are charged and uncharged
In cancer patients, Ixabepilone give a plasma concentration-dependent effect on tubulin dynamics in
peripheral blood mononuclear cells. Ixabepilone has antitumor activity against multiple human tumor
xenografts, including drug-resistant types that overexpress P-gp, MRP-1, and βIII tubulin isoforms, or
harbor tubulin mutations. Ixabepilone is active in xenografts that are resistant to multiple agents including
taxanes, anthracyclines, and vinca alkaloids. Ixabepilone demonstrated synergistic antitumor activity in
combination with capecitabine. Apart from direct antitumor activity, Ixabepilone has antiangiogenic
IXEMPRA™ 45 mg with 23.5 mL of diluent
Diluent of IXEMPRA™ is sterile, non-pyrogenic solution of 52.8% (w/v) purified polyoxyethylated castor oil
and 39.8% (w/v) of dehydrated alcohol, USP. 
IXEMPRA™ (pronounced as ik SEM pra) is a medicine used to treat breast cancer, especially when other
medications do not work or are not working anymore. It could be used alone or with other drug called
IXEMPRA is given by intravenous injection, usually every three weeks. Each injection will take about 3
You are allergic to any ingredients in IXEMPRA™, TAXOL®, which contains Cremophor® EL or
You have low white blood cell count or platelet level
You are taking capecitabine (another cancer drug) and having high liver enzyme levels
You are taking cephalosporins (eg. Cefotetan), disulfiram or metronidazole
WHAT SHOULD I KNOW BEFORE USING IXEMPRA™? 
Before using IXEMPRA™, inform your physician about your medical history which may affect the choice of
Liver problems (including elevation of liver enzymes, hepatitis, cirrhosis, etc.)
Heart diseases (including angina, chest pain, etc.)
Pregnancy, breast-feeding or planning to be pregnant
Current medications, including prescription, non-prescription drugs, herbal or dietary supplements.
They may affect performance of each other.
Cephalosporins (eg. Cefotetan), disulfiram, furazolidone, metronidazole, or sulfonylureas
Azoles (eg. Ketoconazole), delavirdine, fluconazole, clarithromycin, nefazodone, trazodone,
Carbamazepine, barbiturates, dexamethasone, phenytoin, verapamil, rifampin or St. John’s wort
WHAT SHOULD I KNOW DURING USING IXEMPRA™? 
If you experience any allergic reaction to IXEMPRA™, you may need steroid prior future injections of
IXEMPRA™. More slowly administration may be also required.
As IXEMPRA™ contains alcohol, you may be dizzy or drowsy. Avoid operating machinery or driving.
Avoid drinking grapefruit juice while receiving IXEMPRA™ as it may increase the level of IXEMPRA™ and
Your physician should monitor your liver function regularly while you are receiving IXEMPRA™.
Effective contraceptive measures should be employed to prevent pregnancy as IXEMPRA™ may be harmful
WHAT ARE THE POSSIBLE SIDE EFFECTS OF IXEMPRA™? [3, 12, 13]
IXEMPRA™ may cause some serious side effects in individuals. Patients who experience these symptoms
Numbness and tingling of hands or feet may suggest peripheral neuropathy
Fever of 100.5° F or higher or any signs of suspected infection, for example chills, cough, or burning or
pain on urination may suggest neutropenia, which means the fall in white blood cell count.
Uriicaria, pruritus, rash, flushing, swelling, dyspnea or congested chest may suggest hypersensitivity
Suspected or confirmed pregnancy as IXEMPRA™ may be harmful to foetus.
Chest pain, difficulty in breathing, shortness of breathe, palpitations or unusual weight gain may
suggest side effects affecting cardiovascular system.
IXEMPRA™ may also cause milder side effects that may not require special attention:
Patients may experience tiredness, loss of appetite, mild fever, headache, muscle and joint pain,
nausea and vomiting, diarrhea, constipation and abdominal pain
Decrease in red blood cell count (anemia) or platelets (thrombocytopenia)
Changes in toenails and fingernails, hair loss, sores on lip, in the mouth and esophagus
Red palms and soles of feet (hand-foot syndrome) that similar to sunburn, dry and peeling skin
If you find these side effects bothersome or persist for long time, you may inform you physician and seek
for advices. If you experience any other strange side effects, you may also inform your physician.
 National Library of Medicine - Medical Subject Headings, 2006 MeSH, CAS Registry/EC Number (RN)
 FDA News, FDA Approves Ixempra for Advanced Breast Cancer Patients ,October 22, 2007
 Prescribing Information of Ixempra®, 2007, Bristol-Myers-Squibb Company, USA
Available at http://packageinserts.bms.com/pi/pi_ixempra.pdf
 Goodin S et al. Epothilones: Mechanism of Action and Biologic Activity. J Clin. Oncol. 2004; 22:
 Thomas E et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer
Progressing After Anthracycline and Taxane Treatment. J Clin. Oncol. 2007; 25: 5210-5217.
 FDA Approves Ixempra for Advanced Breast Cancer Patients. FDA News Release 22 Oct 2007.
 Lee, James J.; Low, Jennifer A.; Croarkin, Earllaine; Parks, Rebecca; Berman, Arlene W.; Mannan, Nitin;
Steinberg, Seth M.; Swain, Sandra M. Changes in Neurologic Function Tests May Predict Neurotoxicity
Caused by Ixabepilone. Journal of Clinical Oncology. 2006;24(13);pp 2084-2091.
 S. Goel et al. Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of Ixabepilone,
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, 2006 ; 24(18S): 2005
 Sandson Neil B, Drug Interactions Casebook, the cytochrome P450 and beyond. Washington, D.C.:
American Psychiatric Pub., c2003, pp.258-9
 Stockley’s Drug Interactions, London; Chicago : Pharmaceutical Press, 2006
Available at http://www.communityoncology.net/journal/articles/0411660analysis.pdf
 Robert Dreicer, Shuli Li, Judith Manola, Naomi B. Haas, Bruce J. Roth, George Wilding. Phase 2 trial of
epothilone B analog BMS-247550 (Ixabepilone) in advanced carcinoma of the urothelium (E3800).
 Yelle L, Cognetti F, et al. Phase II clinical trial of Ixabepilone (BMS-247550), an epothilone B analog, as
first-line therapy in patients with metastatic breast cancer previously treated with anthracycline
chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Miércoles, 27 de febrero 2002 B.O.C. y L. - N.º 41 II. DISPOSICIONES GENERALES Segunda.– El presente Decreto entrará en vigor al día siguiente de supublicación en el «Boletín Oficial de Castilla y León». Valladolid, a 21 de febrero de 2002. DECRETO 26/2002, de 21 de febrero, por el que se aprueba el Regla - mento deColegios Profesionales de Castilla y León. La Ley 8/1
DAVID A. YEAGER, DPM, FASPS, FACFAS Practice Information: KSB Foot and Ankle Center/ Wound Care Center Dixon, IL 61021 Residency Director of KSB Hospital; Podiatric Medicine and Surgery Residency with Reconstructive Rearfoot/Ankle Surgery Clinical Assistant Professor in the Department of Family and Community Medicine at the University of Illinois College of Medicine at Rockford C